Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial

---

Thiery-Vuillemin A., Saad F., Armstrong A. J., Oya M., Vianna K., ÖZGÜROĞLU M., ...More

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• City: Illinois
• Country: United States Of America
• Istanbul University Affiliated: No